Ambinder, R.
152  Ergebnisse:
Personensuche X
?
1

DARATUMUMAB AND EPOCH FOR HIV+/‐ PLASMABLASTIC LYMPHOMA: A ..:

Noy, A. ; Barta, S. K. ; Tan, C. R....
Hematological Oncology.  41 (2023)  S2 - p. 710-710 , 2023
 
?
2

Clinical outcomes of single-agent chemotherapy in a diverse..:

Weiner, D ; Ly, A ; Talluru, S..
European Journal of Cancer.  173 (2022)  - p. S23 , 2022
 
?
 
?
 
?
6

Dose-adjusted EPOCH chemotherapy with bortezomib and ralteg..:

Ratner, L ; Rauch, D ; Abel, H...
Blood Cancer Journal.  6 (2016)  3 - p. e408-e408 , 2016
 
?
 
?
8

Bortezomib-induced enzyme-targeted radiotherapy (BETR) for ..:

Hobbs, R ; Fu, D ; Pomper, M..
Infectious Agents and Cancer.  4 (2009)  S2 - p. , 2009
 
?
 
?
10

CD4+ T CELL RESPONSES TO EBV NUCLEAR ANTIGENS: 111:

Lemas, M. V. ; Harrington, W. ; Fabian, D....
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.  14 (1997)  4 - p. A44 , 1997
 
?
 
?
12

BOOK REVIEWS:

AMBINDER, R.
JNCI Journal of the National Cancer Institute.  81 (1989)  23 - p. 1833-1834 , 1989
 
?
 
?
 
?
15

Pharmacokinetically-targeted dosed everolimus maintenance t..:

Schoch, L. K. ; Asiama, A. ; Zahurak, M....
Cancer Chemotherapy and Pharmacology.  81 (2017)  2 - p. 347-354 , 2017
 
1-15